#USA #New Haven #Trevi Therapeutics #Haduvio #chronic cough

Trevi Therapeutics Enhances its Position in Treating Chronic Cough

Trevi Therapeutics, Inc. has unveiled its financial results for the last quarter and the entire year of 2024, revealing promising developments in its pursuit of innovative treatment solutions for chronic cough. The highlight of this report was the announcement of positive topline data from the Phase 2a RIVER trial, aiming at patients grappling with refractory chronic cough (RCC). Haduvio, the investigational therapy being advanced by Trevi, notably emerged as the first therapy to demonstrate clinical benefits in patients suffering from this debilitating condition.

In March 2025, Trevi reported significant results from the RIVER trial, where Haduvio achieved a marked reduction in 24-hour cough frequency. The study included 66 patients and displayed a statistically significant change that was 57% over the placebo, indicating that Haduvio could effectively alleviate severe cough in its patient population. "With Haduvio, we are addressing an urgent and unmet medical need for individuals battling chronic cough conditions where no approved treatments currently exist in the U.S.," said Jennifer Good, CEO of Trevi Therapeutics.

The company also announced successful enrollment completion in the Phase 2b CORAL trial aimed at IPF patients with chronic cough, a key development in Trevi's pipeline. Anticipated topline results from this trial are expected in the second quarter of 2025, further enhancing the outlook for Haduvio.

Financial Overview and Business Highlights

The financial report showcased a year of substantial growth amidst increasing research and development costs. In the fourth quarter of 2024, Trevi's research and development expenses mounted to $9.3 million, up from $6.5 million in the prior year, attributed mainly to escalated development costs associated with ongoing clinical trials. General and administrative expenses also saw a rise, reaching $2.9 million in Q4 2024, largely due to increased stock-based compensation and personnel expenses.

In total, Trevi reported a net loss of $11.4 million for the last quarter of 2024, compared to a net loss of $7.8 million reported in the same period the previous year. For the full year, the company faced a net loss of $47.9 million, significantly larger than the $29.1 million it lost in 2023. However, Trevi ended the year with a robust cash position of $107.6 million, with a cash runway expected to last into the second half of 2026, providing a solid foundation for ongoing and future clinical trials.

Future Prospects

The upcoming topline results for the CORAL trial could potentially reshape the treatment landscape for chronic cough. The interim analysis reaffirming the original study sample size gives Trevi confidence in the robustness of its clinical approach. Following the release of these results, Trevi also plans to consult with regulatory bodies on the next steps for Haduvio, signaling an attentiveness to aligning its clinical advancements with regulatory expectations.

Trevi’s strategy reflects a commitment to developing multifaceted solutions for chronic cough through Haduvio, which operates on kappa and mu opioid receptors responsible for cough reflex control.

As Trevi prepares to participate in multiple healthcare conferences in the upcoming weeks, it remains poised to showcase its advancements while addressing the significant demands in the field of respiratory health. Stakeholders will be eagerly watching how Trevi navigates its promising data and financial strategies to fulfill its commitment to bringing innovative therapies to the market, especially in an area with pressing unmet medical needs.

For updates on Trevi Therapeutics, visit their website and follow their social media channels for real-time news and announcements.